C

Capricor Therapeutics
D

CAPR

18.500
USD
0.71
(3.99%)
Market Open
Volume
33,652
EPS
-1
Div Yield
-
P/E
-18
Market Cap
840,283,900
News

Title: Capricor Therapeutics

Sector: Healthcare
Industry: Biotechnology
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.